Comparative Pharmacology
Head-to-head clinical analysis: TAZVERIK versus XOSPATA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAZVERIK versus XOSPATA.
TAZVERIK vs XOSPATA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TAZVERIK is a histone methyltransferase EZH2 inhibitor. It selectively inhibits the enzymatic activity of EZH2, leading to decreased trimethylation of lysine 27 on histone H3 (H3K27me3), which results in reactivation of silenced genes and inhibition of proliferation in EZH2-mutant or wild-type cells.
Gilteritinib is a tyrosine kinase inhibitor that inhibits FLT3 (FMS-like tyrosine kinase 3) receptor signaling, including FLT3-ITD and FLT3-TKD mutations, leading to apoptosis in leukemic cells.
600 mg orally twice daily, with or without food, for advanced epithelioid sarcoma. Continue until disease progression or unacceptable toxicity.
120 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 3.6 hours (range 1.6–7.1 hours) in patients with epithelioid sarcoma at steady state. Short half-life supports twice-daily dosing. Consider accumulation with renal or hepatic impairment.
Terminal half-life 9.1 hours (range 4.4–16.1 hours); supports once-daily dosing.
Primarily hepatobiliary excretion: approximately 70% of the dose recovered in feces as unchanged drug and metabolites, with <1% excreted renally as unchanged tazemetostat.
Fecal (64%) and renal (16%) as metabolites; <1% unchanged in urine.
Category C
Category C
Antineoplastic, EZH2 Inhibitor
Antineoplastic